Cost-effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti-FVIII inhibitors in France.
Benoît PolackMarc TrossaërtMathias CousinSandrine BaffertAlexandra PruvotChloé GodardPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2020)
Our results show that emicizumab is a cost-effective treatment allowing to consider an easy to implement prophylactic treatment for haemophilia A patients with anti-FVIII inhibitors.
Keyphrases